{"altmetric_id":6091413,"counts":{"readers":{"mendeley":12,"citeulike":0,"connotea":0},"total":{"posts_count":1},"news":{"unique_users_count":1,"unique_users":["seeking_alpha"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa5e93cf058f610005a18","authors":["Monk BJ","Sill MW","Burger RA","Gray HJ","Buekers TE","Roman LD","Bradley J. Monk","Michael W. Sill","Robert A. Burger","Heidi J. Gray","Thomas E. Buekers","Lynda D. Roman"],"doi":"10.1200\/jco.2008.18.9043","endpage":"1074","first_seen_on":"2016-03-04T22:14:28+00:00","issns":["0732-183X","1527-7755"],"issue":"7","journal":"Journal of Clinical Oncology","last_mentioned_on":1490967071,"links":["https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19139430"],"pmcid":"PMC2667811","pmid":"19139430","pubdate":"2009-03-01T00:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"startpage":"1069","subjects":["neoplasms"],"title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.","type":"article","volume":"27","mendeley_url":"http:\/\/www.mendeley.com\/research\/phase-ii-trial-bevacizumab-treatment-persistent-recurrent-squamous-cell-carcinoma-cervix-gynecologic-3"},"altmetric_score":{"score":7,"score_history":{"1y":7,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":8440126,"mean":7.0979478654558,"rank":1239577,"this_scored_higher_than_pct":84,"this_scored_higher_than":7124406,"rank_type":"exact","sample_size":8440126,"percentile":84},"similar_age_3m":{"total_number_of_other_articles":288776,"mean":11.075562531382,"rank":58080,"this_scored_higher_than_pct":78,"this_scored_higher_than":227351,"rank_type":"exact","sample_size":288776,"percentile":78},"this_journal":{"total_number_of_other_articles":8989,"mean":15.295635514019,"rank":2901,"this_scored_higher_than_pct":65,"this_scored_higher_than":5904,"rank_type":"exact","sample_size":8989,"percentile":65},"similar_age_this_journal_3m":{"total_number_of_other_articles":284,"mean":27.898233215548,"rank":151,"this_scored_higher_than_pct":46,"this_scored_higher_than":132,"rank_type":"exact","sample_size":284,"percentile":46}}},"demographics":{"users":{"mendeley":{"by_status":{"Student  > Doctoral Student":1,"Researcher":3,"Student  > Ph. D. Student":2,"Other":1,"Student  > Master":3,"Student  > Bachelor":1,"Professor":1},"by_discipline":{"Medicine and Dentistry":6,"Agricultural and Biological Sciences":4,"Biochemistry, Genetics and Molecular Biology":1,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"mendeley":{"CN":1}}},"posts":{"news":[{"title":"Investing In Advaxis: Biotech Gold Or Bust","url":"http:\/\/ct.moreover.com\/?a=30081558828&p=1pl&v=1&x=lz2Fn23IURcwG0QoNsG2gQ","license":"public","citation_ids":[18353573,2132655,6091413,521217],"posted_on":"2017-03-31T13:31:11+00:00","summary":"Advaxis, Inc (NASDAQ: ADXS ), like many stocks in speculative biotech, has been a rollercoaster ride throughout the past several years.","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}}]}}